Research Article
Usefulness of Soluble Transferrin Receptor in the Diagnosis of Iron Deficiency Anemia in Rheumatoid Arthritis Patients in Clinical Practice
Table 1
Characteristics of patients under study. Data are given as
. Ranges are given in brackets and percentages in parentheses.
| | Number | 116 | | Age, yr | [29–92] | | Women/men | 57/57 (50/50) | | Hb (g/dl), women | [8.9–11.9] | | Hb (g/dl), men | [8.6–13.8] | | Creatinine, mg/dl | [0.47-2.34] | | Autoantibodies | | | Without any | 53 (46) | | RF | 60 (52) | | ACPA | 58 (50) | | RF and ACPA | 54 (47) | | Classification of anemia | | | IDA | 6 (5) | | ACD | 60 (52) | | IDA/ACD | 36 (31) | | Other anemia | 14 (12) | | Indicators of disease activity | | | CRP, mg/l | [0.1-269.3] | | ESR, mm/hour | 46.6 (±31.0) [2–120] | | DAS28 score | 4.6 (±1.6) [0.8–9.2] | | Indicators of iron status | | | MCV, μm3 | 88.0 (±6.1) [73–107] | | MCH, pg | 29.3 (±3.4) [23–35] | | Ferritin, ng/ml | 266.2 (±300.1) [10–1272] | | Iron, μg/dl | 49.1 (±25.7) [10–118] | | Transferrin g/l | 1.3 (±0.6) [1.4–3.8] | | TSAT, % | 15.8 (±8.5) [2.9–62.2] | | sTfR, mg/l | 4.4 (±2.0) [2.2–13.6] | | Immunosuppressive therapy | | | None | 29 (25.0) | | Prednisolone mono low dose (≤7.5 mg/die) | 26 (22.4) | | csDMARD | 41 (35.3) | | bDMARD/tsDMARD | 20 (17.2) | | Anti-TNF | 5 (4.3) | | Abatacept | 3 (2.6) | | RTX | 6 (5.2) | | Anti-Il-6 | 4 (3.4) | | JAK-I | 2 (1.7) | | Comorbidities | | | Arterial hypertension | 71 (61.2) | | Cardiovascular disease (coronary heart disease, peripheral arterial disease, heart failure, and state after cerebral ischemia) | 28 (24.1) | | Absolute arrhythmia | 20 (17.2) | | Chronic renal insufficiency | 13 (12.1) | | Asthma | 4 (3.4) | | COPD | 3 (2.6) | | Hyperlipidemia | 13 (12.1) | | Diabetes mellitus type 2 | 20 (17.2) |
|
|
Abbreviations: SD: standard deviation; Hb: hemoglobin; RF: rheumatoid factor; ACPA: anticitrullinated peptide antibody; IDA: iron deficiency anemia; ACD: anemia of chronic disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DAS28: disease activity score in 28 joints; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; sTfR: soluble transferrin receptor; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARD: biologic disease-modifying antirheumatic drugs; tsDMARD: targeted synthetic disease-modifying antirheumatic drugs; RTX: rituximab; anti-Il-6: anti-interleukin-6 antibody; JAK-I: janus kinase inhibitor; COPD: chronic obstructive pulmonary disease.
|
